Nurami Medical has been accepted to the In-Ventech Growth Stage Program
Nurami Medical has been accepted to the In-Ventech Growth Stage Program – a unique stratup program for post-pilot stage companies, backed
Nurami Medical at CNS 2022 Annual Meeting in San Francisco
See Nurami Medical’s team at the 2022 CNS Annual Meeting in San-Francisco
Nurami Medical announces positive results from its brain surgery clinical trial
Nurami Medical, which is developing a biodegradable surgical patch for Dura repair in neurosurgeries, has achieved its key endpoint in its clinical
Nurami Medical to attend the CNS 2022 Annual Meeting in San Francisco in October
Let’s meet at CNS 2022. Contact us to set up a meeting.
Dr. Amir Bahar presents ArtiFascia, our novel solution for Dural repair at AACNS022, in
September.
Nurami presented its novel technology at its booth and in a presentation given by Nurami COO, Dr. Amir Bahar.
Nurami welcomes Noam Sorek, its new VP of Business Development
As it nears commercialization, Noam Sorek, a seasoned BD executive, with experience in launching medical device sales in international markets, joins Nurami.
Nurami welcomes Peter Stebbins, its new Executive Chair of the Board
Entrepreneurial MedTech leader, Peter Stebbins joins Nurami’s team
Nurami Medical finishes recruitment for tissue damage clinical trial
Nurami Medical has recruited all the patients for a clinical trial on its product, ArtiFascia, a synthetic implant for restoring and repairing
Nurami seeks FDA, EU approval for soft tissue repair solution
Nurami Medical has recruited all the patients for a clinical trial on its product to repair soft tissue damaged during neurosurgery
Nurami Medical Raises $5 Million Round Led by Almeda Ventures
Nurami Medical, a medical device R&D company, which is developing a groundbreaking technology that facilitates post-surgical healing of soft tissues, has
